

# Meng Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6481005/publications.pdf>

Version: 2024-02-01

17  
papers

155  
citations

1307594

7  
h-index

1199594

12  
g-index

17  
all docs

17  
docs citations

17  
times ranked

191  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of liver transplantation in methylmalonic and propionic acidemias. <i>Liver Transplantation</i> , 2015, 21, 1208-1218.	2.4	27
2	Effects of Cranberry Juice on Pharmacokinetics of $\beta$ -Lactam Antibiotics following Oral Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2725-2732.	3.2	22
3	Do cancer treatments have option value? Real-world evidence from metastatic melanoma. <i>Health Economics (United Kingdom)</i> , 2019, 28, 855-867.	1.7	15
4	How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. <i>Value in Health</i> , 2019, 22, 777-784.	0.3	14
5	Estimating the Cost of Illness of Giant Cell Arteritis in the United States. <i>Rheumatology and Therapy</i> , 2017, 4, 111-119.	2.3	12
6	Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 4, 17-21.	4.5	12
7	Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 400-406.	0.9	10
8	Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018. <i>JAMA Network Open</i> , 2021, 4, e219030.	5.9	9
9	Assessment of the scope and practice of evaluation among medical donation programs. <i>Globalization and Health</i> , 2016, 12, 69.	4.9	7
10	Association Between Spending and Outcomes for Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 323-331.	1.6	7
11	Spending On Targeted Therapies Reduced Mortality In Patients With Advanced-Stage Breast Cancer. <i>Health Affairs</i> , 2021, 40, 763-771.	5.2	5
12	Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data. <i>Value in Health</i> , 2021, 24, 1746-1753.	0.3	5
13	A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. <i>Value in Health</i> , 2022, 25, 1878-1884.	0.3	4
14	Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2022, 40, 623-631.	3.3	3
15	Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey. <i>Journal of General Internal Medicine</i> , 2020, 35, 1334-1336.	2.6	1
16	Real-world evidence for option value in metastatic melanoma. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1-10.	0.9	1
17	Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1750-1756.	0.9	1